Vastiras (human atrial natriuretic factor prohormone 31-67) / Madeleine Pharma - LARVOL DELTA

FTIR Analysis of Renal Tissue for the Assessment of Hypertensive Organ Damage and proANP Treatment. (PubMed, Int J Mol Sci) - "FTIR micro-imaging was found to be a reliable tool for monitoring the remarkable heterogeneity of kidney tissue and its hypertension-induced alterations. In addition, FTIR detected a significant reduction in these hypertension-induced alterations in the kidneys of proANP-treated rats, further indicating the high sensitivity of this cutting-edge imaging modality and the beneficial effects of this novel medication on the kidneys."

Journal • Cardiovascular • Hypertension • Nephrology • Renal Disease

Atrial Natriuretic Peptide: A Novel Therapeutic Factor for Cardiovascular Diseases. (PubMed, Front Physiol) - "We further highlight recent evidence on the cardiorenal protective actions of chronic supplementation of synthetic proANP in preclinical models of cardiorenal disease. Finally, we evaluate the use of proANP as a new therapeutic strategy to repair end-organ damage secondary to hypertension, diabetes mellitus, renal diseases, obesity, heart failure, and other morbidities that can lead to impaired cardiac function and structure."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Obesity • Renal Disease

[VIRTUAL] Low dose of proANP31-67 does not affect kidney function/structure, but prevents adverse cardiac remodeling independent of blood pressure regulation (HEART FAILURE-I 2020) - "Conclusion(s) Low dose of proANP31–67 has subtherapeutic effect on kidney function and does not reduce blood pressure in a chronic model of hypertension-induced cardiac hypertrophy. However, RSD of proANP31–67 has tangible cardioprotective effects suggesting a unique mode of action on the heart beyond its known actions on the kidney and reduction of blood pressure."

Cardiovascular • Dyslipidemia

Cardioprotective Effects of the Novel Compound Vastiras in a Preclinical Model of End-Organ Damage. (PubMed, Hypertension) - "At the cellular level, cardiomyocyte size and t-tubule density were preserved in Vastiras-treated compared with untreated animals. In conclusion, these data demonstrate the cardiorenal protective actions of chronic supplementation of a first-in-class compound, Vastiras, in a preclinical model of maladaptive cardiac hypertrophy and renal damage induced by hypertension."

Journal • Preclinical

CARDIORENAL PROTECTIVE EFFECTS OF PRO-ATRIAL-NATRIURETIC-PEPTIDE (31-67) INDEPENDENT OF BLOOD PRESSURE (ESH 2019) - "These data demonstrate the cardiorenal protective actions of chronic supplementation of a first in class compound, proANP31-67, which preserved kidney and heart structure/function, without reducing systemic blood pressure, in a preclinical model of maladaptive cardiac hypertrophy induced by hypertension."